InflaRx NV at HC Wainwright Investment Conference - New York Transcript
Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve Bersey. I'm an equity research associate here at H.C. Wainwright and it's my pleasure to introduce Niels C. Riedemann, CEO of InflaRx. So I'll turn it over to Neils.
Thank you so much, also for having us here today. We are happy to present. I'm here with our team Dr. Camilla Chong, our Chief Medical Officer, and Dr. Thomas Taapken, our CFO. So happy to go into the presentation right away. We had also some data released today, which I will spend a bit time on as well. So we're excited about that. But before I start, please take note of our corporate disclaimer, I'll be making forward-looking statements and also comparisons to published data of other molecules. So please take note of the disclaimer.
So when looking at our pipeline we are really in the terminal complement C5a, C5aR are spaced now with two very
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
